Richmond Pharmacology CEO Dr Jörg Täubel Appointed President of AGAH

London, UK — Richmond Pharmacology announces that its Chief Executive Officer and Co-Founder, Dr Jörg Täubel, has assumed the presidency of the Association for Applied Human Pharmacology (AGAH), the leading German organisation dedicated to advancing clinical pharmacology and early-phase medicines research. AGAH brings together experts from pharmaceutical companies, academia, contract research organisations and regulatory authorities who are involved in clinical pharmacology programmes and translational research supporting early-stage drug development.

Dr Täubel’s six-year leadership term within AGAH spans three phases: President-Elect (2024–2026), President (2026–2028) and Past President (2028–2030). Dr Täubel formally took over the Presidency at the AGAH Annual Conference in Frankfurt last month where he set out his vision for modernising engagement within the human pharmacology community. 

In his inauguration speech Dr Täubel said:" During my presidency, I aim to expand AGAH's engagement across online platforms to accelerate the sharing of drug development knowledge and strengthen collaboration across our community."

I am also committed to enhancing the AGAH’s ability to inspire more young people to lead more trials in the future. AGAH has a key role to play in growing the pool of doctors and other professionals active in early phase clinical research and to work constructively with stakeholders to provide important input into guidelines governing the testing of potential new medicines.”

Dr Täubel is a recognised leader in experimental medicine and early clinical development. As CEO and co-founder of Richmond Pharmacology, he has served as principal investigator in more than 500 clinical trials across Phase I–III studies and is an MHRA-recognised investigator for first-in-human trials.

He led the dosing of the first patient in the landmark NTLA-2001 clinical study, the first in vivo CRISPR-Cas9 gene editing therapy for transthyretin amyloidosis. Richmond Pharmacology has since become a leading global centre for in vivo gene-editing studies.

Dr Täubel co-founded Richmond Pharmacology in 2001 and also established the Richmond Research Institute, a not-for-profit organisation dedicated to advancing academic medical research.

Educated at Goethe-Universität Frankfurt, Dr Taubel is a Fellow of the European Society of Cardiology, the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom and the Royal Society of Medicine. He is an honorary senior research fellow at St George’s University of London and a visiting professor at King’s College London.

ENDS

Imagery:

See attached

Media Contact:
Linda Rose

Linda@denhams.digital
Denham’s Digital

About Richmond Pharmacology:

Founded in 2001, Richmond Pharmacology is a leading Contract Research Organisation (CRO) with a heritage in first-in-human and adaptive clinical trials. It has conducted around 20% of all UK Phase I studies and has recognised expertise in advanced modalities, including in-vivo gene editing. Richmond dosed the first patient in the world with a systemically delivered, in‑vivo CRISPR–Cas9 therapeutic, marking a global milestone in genomic medicine.

Today, Richmond supports global pharmaceutical, biotech, and genetic engineering partners, including a wide range of global pharmaceutical and biotechnology partners. In 2020, it established the Richmond Research Institute to expand understanding of under-researched diseases.

About AGAH

The Association for Applied Human Pharmacology (AGAH) is a scientific organisation dedicated to advancing clinical pharmacology and translational medicine. Its members include professionals from pharmaceutical companies, universities, contract research organisations and regulatory authorities working in early-phase drug development and human pharmacology research.